At ACADIA, we remain deeply committed to providing important new therapies to patients and delivering value for our stockholders. Our Investor Center is designed to provide you with convenient access to company information.

Recent News

- 2Q20 Net Sales of $110.1 Million , a 32% Increase Over 2Q19 - FDA filed the supplemental NDA for pimavanserin for the treatment of dementia-related psychosis with a PDUFA action date set for April 3, 2021 - Initiated ADVANCE-2, a Phase 3 study evaluating pimavanserin for the treatment of the
- Key findings presented at AAIC 2020 include: a need to improve patients’ symptoms and ability to know what is real versus what is not real - When asked to rank the impact on their own life, patients reported that visual hallucinations were the most impactful symptom - Care partners reported
ACADIA to Host Conference Call and Webcast on Wednesday, August 5, 2020 , at 4:30 p.m. Eastern Time   SAN DIEGO --(BUSINESS WIRE)--Jul. 22, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 5, 2020 , after the